Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
Main Author: | |
---|---|
Publication Date: | 2013 |
Other Authors: | , , , , , , , |
Format: | Article |
Language: | eng |
Source: | Clinics |
Download full: | https://www.revistas.usp.br/clinics/article/view/72131 |
Summary: | OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome. METHODS: A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed between 1992 and 2011. The IPSS and Lille scores were calculated for risk stratification and correlated with overall survival. RESULTS: A V617F JAK2 mutation was detected in 32 cases (47%), with no significant correlation with overall survival. The patients were classified according to the scores: Lille - low, 53 (73.%); intermediate, 13 (18%); and high, 5 (7%); and IPSS- low, 15 (26%); intermediate-1, 23 (32%); intermediate-2, 19 (26%); and high, 15 (31%). Those patients presenting a higher risk according to the IPSS (high and intermediate-2) had a significantly shorter overall survival relative to the low risk groups (intermediate-1 and low) (p = 0.02). CONCLUSIONS: These results emphasize the importance of the IPSS prognostic score for risk assessment in predicting the clinical outcome of primary myelofibrosis patients. |
id |
USP-19_541f092c142ac51517cbc355bef18315 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/72131 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcomePrimary MyelofibrosisIPSSPrognosisOBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome. METHODS: A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed between 1992 and 2011. The IPSS and Lille scores were calculated for risk stratification and correlated with overall survival. RESULTS: A V617F JAK2 mutation was detected in 32 cases (47%), with no significant correlation with overall survival. The patients were classified according to the scores: Lille - low, 53 (73.%); intermediate, 13 (18%); and high, 5 (7%); and IPSS- low, 15 (26%); intermediate-1, 23 (32%); intermediate-2, 19 (26%); and high, 15 (31%). Those patients presenting a higher risk according to the IPSS (high and intermediate-2) had a significantly shorter overall survival relative to the low risk groups (intermediate-1 and low) (p = 0.02). CONCLUSIONS: These results emphasize the importance of the IPSS prognostic score for risk assessment in predicting the clinical outcome of primary myelofibrosis patients.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2013-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/7213110.1590/clin.v68i3.72131Clinics; v. 68 n. 3 (2013); 339-343Clinics; Vol. 68 Núm. 3 (2013); 339-343Clinics; Vol. 68 No. 3 (2013); 339-3431980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/72131/75366Benites, Bruno DeltreggiaLima, Carolina Silva CostaLorand-Metze, IreneDelamain, Marcia TorresanOliveira, Gislaine BorbaAlmeida, Daiane deSouza, Carmino Antonio deVassallo, JosePagnano, Katia Borgia Barbosainfo:eu-repo/semantics/openAccess2014-01-28T17:05:36Zoai:revistas.usp.br:article/72131Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2014-01-28T17:05:36Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome |
title |
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome |
spellingShingle |
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome Benites, Bruno Deltreggia Primary Myelofibrosis IPSS Prognosis |
title_short |
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome |
title_full |
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome |
title_fullStr |
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome |
title_full_unstemmed |
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome |
title_sort |
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome |
author |
Benites, Bruno Deltreggia |
author_facet |
Benites, Bruno Deltreggia Lima, Carolina Silva Costa Lorand-Metze, Irene Delamain, Marcia Torresan Oliveira, Gislaine Borba Almeida, Daiane de Souza, Carmino Antonio de Vassallo, Jose Pagnano, Katia Borgia Barbosa |
author_role |
author |
author2 |
Lima, Carolina Silva Costa Lorand-Metze, Irene Delamain, Marcia Torresan Oliveira, Gislaine Borba Almeida, Daiane de Souza, Carmino Antonio de Vassallo, Jose Pagnano, Katia Borgia Barbosa |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Benites, Bruno Deltreggia Lima, Carolina Silva Costa Lorand-Metze, Irene Delamain, Marcia Torresan Oliveira, Gislaine Borba Almeida, Daiane de Souza, Carmino Antonio de Vassallo, Jose Pagnano, Katia Borgia Barbosa |
dc.subject.por.fl_str_mv |
Primary Myelofibrosis IPSS Prognosis |
topic |
Primary Myelofibrosis IPSS Prognosis |
description |
OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome. METHODS: A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed between 1992 and 2011. The IPSS and Lille scores were calculated for risk stratification and correlated with overall survival. RESULTS: A V617F JAK2 mutation was detected in 32 cases (47%), with no significant correlation with overall survival. The patients were classified according to the scores: Lille - low, 53 (73.%); intermediate, 13 (18%); and high, 5 (7%); and IPSS- low, 15 (26%); intermediate-1, 23 (32%); intermediate-2, 19 (26%); and high, 15 (31%). Those patients presenting a higher risk according to the IPSS (high and intermediate-2) had a significantly shorter overall survival relative to the low risk groups (intermediate-1 and low) (p = 0.02). CONCLUSIONS: These results emphasize the importance of the IPSS prognostic score for risk assessment in predicting the clinical outcome of primary myelofibrosis patients. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/72131 10.1590/clin.v68i3.72131 |
url |
https://www.revistas.usp.br/clinics/article/view/72131 |
identifier_str_mv |
10.1590/clin.v68i3.72131 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/72131/75366 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; v. 68 n. 3 (2013); 339-343 Clinics; Vol. 68 Núm. 3 (2013); 339-343 Clinics; Vol. 68 No. 3 (2013); 339-343 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1787713176194777088 |